ATE479687T1 - Kinaseinhibitoren - Google Patents

Kinaseinhibitoren

Info

Publication number
ATE479687T1
ATE479687T1 AT05810353T AT05810353T ATE479687T1 AT E479687 T1 ATE479687 T1 AT E479687T1 AT 05810353 T AT05810353 T AT 05810353T AT 05810353 T AT05810353 T AT 05810353T AT E479687 T1 ATE479687 T1 AT E479687T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
kinases
kits
variables
compounds
Prior art date
Application number
AT05810353T
Other languages
German (de)
English (en)
Inventor
Qing Dong
David Hosfield
Bheema R Paraselli
Nicholas Scorah
Jeffrey A Stafford
Michael Wallace
Zhiyuan Zhang
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35677430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE479687(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE479687T1 publication Critical patent/ATE479687T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AT05810353T 2004-10-15 2005-10-14 Kinaseinhibitoren ATE479687T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61930204P 2004-10-15 2004-10-15
US67969005P 2005-05-11 2005-05-11
PCT/US2005/037059 WO2006044687A2 (en) 2004-10-15 2005-10-14 Kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE479687T1 true ATE479687T1 (de) 2010-09-15

Family

ID=35677430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810353T ATE479687T1 (de) 2004-10-15 2005-10-14 Kinaseinhibitoren

Country Status (6)

Country Link
US (2) US7713973B2 (enExample)
EP (1) EP1812439B2 (enExample)
JP (3) JP2008516973A (enExample)
AT (1) ATE479687T1 (enExample)
DE (1) DE602005023333D1 (enExample)
WO (1) WO2006044687A2 (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572514A4 (en) * 2002-10-16 2007-09-26 Transp Systems Inc DISTRIBUTION SYSTEM FOR ONE RAILWAY
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
NZ564065A (en) * 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7232901B2 (en) * 2005-07-01 2007-06-19 Bristol-Myers Squibb Company Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
US7442700B2 (en) * 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
CN102335163A (zh) * 2005-07-18 2012-02-01 彼帕科学公司 癌症的治疗
EP1928456B1 (en) * 2005-09-30 2015-04-22 Miikana Therapeutics, Inc. Substituted pyrazole compounds
TW200808788A (en) * 2006-04-19 2008-02-16 Astellas Pharma Inc Azolecarboxamide derivative
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2041138B1 (en) * 2006-07-07 2014-06-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7605160B2 (en) * 2006-08-09 2009-10-20 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP2010502731A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
AR063581A1 (es) * 2006-11-08 2009-02-04 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa
US8148522B2 (en) * 2007-01-02 2012-04-03 Bristol-Myers Squibb Company Intermediate useful in preparing certain pyrrolotriazine compounds and a process for making the intermediate
ES2353630T3 (es) * 2007-01-08 2011-03-03 Bristol-Myers Squibb Company Productos intermedios útiles en la preparación de determinados compuestos de pirrolotriazina y un procedimiento de fabricación de productos intermedios.
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
JP2010522241A (ja) 2007-03-21 2010-07-01 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
WO2008131050A1 (en) * 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2683152A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
ES2498065T3 (es) * 2007-10-24 2014-09-24 Astellas Pharma Inc. Compuesto de azolcarboxamida o sal del mismo
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
AU2008321128A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
US20090149397A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
DE102008035209A1 (de) 2008-07-29 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102007060172A1 (de) 2007-12-13 2009-06-25 Bayer Healthcare Ag Triazolotriazine und Triazolopyrazine und ihre Verwendung
PE20091074A1 (es) * 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
ES2548131T3 (es) * 2008-01-08 2015-10-14 Merck Sharp & Dohme Limited Sales farmacéuticamente aceptables de 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
CA2710929A1 (en) * 2008-01-28 2009-08-06 Schering Corporation Imidazopyrazines as protein kinase inhibitors
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
WO2010011837A1 (en) 2008-07-24 2010-01-28 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2010042684A1 (en) * 2008-10-08 2010-04-15 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN104744476B (zh) 2008-12-08 2017-04-12 吉利德康涅狄格公司 咪唑并吡嗪syk抑制剂
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
SG171993A1 (en) * 2008-12-08 2011-07-28 Gilead Connecticut Inc Imidazopyrazine syk inhibitors
JP5487214B2 (ja) * 2008-12-19 2014-05-07 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
JP5667085B2 (ja) * 2009-02-13 2015-02-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔインヒビターとしての融合されたピリミジン
JP2012529535A (ja) 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
WO2011088045A1 (en) 2010-01-12 2011-07-21 Ambit Biosciences Corporation Aurora kinase compounds and methods of their use
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
JP5093527B2 (ja) * 2010-02-10 2012-12-12 日本電気株式会社 複合光導波路、波長可変フィルタ、波長可変レーザ、および光集積回路
NZ602362A (en) 2010-03-11 2014-11-28 Gilead Connecticut Inc Imidazopyridines syk inhibitors
UA109131C2 (ru) * 2010-04-14 2015-07-27 Еррей Біофарма Інк. 5,7-ЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-c]ПИРИМИДИНЫ КАК ИНГИБИТОРЫ JAK-КИНАЗ
WO2011141713A1 (en) 2010-05-13 2011-11-17 Centro Nacional De Investigaciones Oncologicas (Cnio) New bicyclic compounds as pi3-k and mtor inhibitors
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
WO2012114222A1 (en) 2011-02-23 2012-08-30 Pfizer Inc. IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CA2916504A1 (en) 2013-06-25 2014-12-31 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
UY35625A (es) 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
EP3027171B1 (en) 2013-07-30 2020-03-25 Gilead Connecticut, Inc. Formulation of syk inhibitors
EA201791873A1 (ru) 2013-07-30 2018-09-28 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
KR20180002888A (ko) 2013-12-04 2018-01-08 길리애드 사이언시즈, 인코포레이티드 암을 치료하는 방법
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
CN106687139A (zh) 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
EP3461821B1 (en) 2014-10-24 2020-05-13 Bristol-Myers Squibb Company Indole carboxamide compounds useful as kinase inhibitors
SG11201703186RA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds
BR112017007545A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co derivados de carbazol
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MX2018005342A (es) 2015-11-02 2018-08-15 Janseen Pharmaceutica Nv Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo.
HUE060680T2 (hu) 2015-11-19 2023-04-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
DK3394033T3 (da) 2015-12-22 2021-01-04 Incyte Corp Heterocykliske forbindelser som immunmodulatorer
WO2017148391A1 (zh) * 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112019008163A2 (pt) 2016-11-02 2019-07-09 Janssen Pharmaceutica Nv compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
ES2912264T3 (es) 2016-11-02 2022-05-25 Janssen Pharmaceutica Nv Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2
SG11201903892UA (en) 2016-11-02 2019-05-30 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
MA47123A (fr) 2016-12-22 2021-03-17 Incyte Corp Dérivés de benzooxazole en tant qu'mmunomodulateurs
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
CN111217797B (zh) * 2017-06-30 2021-02-05 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN111051311A (zh) 2017-08-25 2020-04-21 吉利德科学公司 Syk抑制剂的多晶型物
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US10669271B2 (en) 2018-03-30 2020-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
LT3790877T (lt) 2018-05-11 2023-05-10 Incyte Corporation Tetrahidro-imidazo[4,5-c]piridino dariniai kaip pd-l1 imunomoduliatoriai
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CA3105721A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
US12297184B2 (en) 2018-10-03 2025-05-13 Tesaro, Inc. Niraparib salts
CN111018860B (zh) * 2018-10-10 2022-06-10 中国药科大学 吡咯并三嗪类化合物及其应用
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
EP4157848A4 (en) * 2020-06-01 2024-07-17 Nanjing Ruijie Pharma Co., Ltd. COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS
WO2022099071A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
AU2023249795A1 (en) 2022-04-08 2024-10-17 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB828847A (en) 1956-12-14 1960-02-24 Ilford Ltd Improvements in or relating to cyanine dyes
FR1242962A (fr) 1959-08-25 1960-10-07 Kodak Pathe Nouveau procédé pour la préparation de colorants sensibilisateurs de la série des cyanines et des mérocyanines et produits obtenus
IT7919536A0 (it) 1978-01-25 1979-01-23 Bayer Ag Coloranti eterociclici.
DE2844606A1 (de) 1978-10-13 1980-04-24 Bayer Ag Heterocyclische farbstoffe
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5962312A (en) 1995-12-18 1999-10-05 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
ATE342971T1 (de) 1997-08-15 2006-11-15 Univ Hiroshima Den zellzyklus regulierende proteine
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6143480A (en) 1998-09-03 2000-11-07 Fuji Photo Film Co., Ltd. Leuco dye and image recording medium containing the same
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US20050113460A1 (en) 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
NZ516292A (en) * 1999-05-21 2004-01-30 Bristol Myers Squibb Co Pyrrolotriazine inhibitors of kinases
WO2001007466A1 (en) 1999-07-21 2001-02-01 University Of Massachusetts Kinase blocking polypeptides and uses thereof
JP4623483B2 (ja) * 1999-08-23 2011-02-02 塩野義製薬株式会社 ｓＰＬＡ２阻害作用を有するピロロトリアジン誘導体
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
HUP0204413A3 (en) 1999-09-21 2003-07-28 Astrazeneca Ab Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
MXPA02006338A (es) 1999-12-24 2002-12-13 Aventis Pharma Ltd Azaindoles.
AU2001228638A1 (en) 2000-01-28 2001-08-07 Astrazeneca Ab Chemical compounds
AU782775B2 (en) 2000-02-05 2005-08-25 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of ERK
AU782878B2 (en) 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
EP1134221A1 (en) 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
EP1209158A1 (en) 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Substituted beta-carbolines
JP2001294772A (ja) 2000-04-10 2001-10-23 Fuji Photo Film Co Ltd 着色組成物、インクジェット用インク及びインクジェット記録方法
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
EE200200715A (et) 2000-06-28 2004-08-16 Astrazeneca Ab Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
CN102060857A (zh) 2000-08-10 2011-05-18 辉瑞意大利有限公司 具有激酶抑制剂活性的二环吡唑类、其制备方法和包含它们的药物组合物
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
AU2002215053A1 (en) 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
US6455559B1 (en) 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
MXPA03004714A (es) 2000-11-28 2003-08-19 Pfizer Prod Inc Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion.
FR2818278B1 (fr) * 2000-12-20 2003-02-28 Sod Conseils Rech Applic Inhibiteurs de kinases dependantes des cyclines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
WO2002050079A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
AP2003002825A0 (en) 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
JP3779682B2 (ja) 2001-05-14 2006-05-31 ファイザー・プロダクツ・インク ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタンの酒石酸塩及びその医薬組成物
US20050090498A1 (en) 2001-05-24 2005-04-28 Kiyohiro Samizu 3-Quinolin-2(1h)-ylideneindolin-2-one derivative
JP2004534779A (ja) 2001-05-30 2004-11-18 エルジー ライフサイエンス リミテッド 疾病治療用プロテインキナーゼ阻害剤
MXPA03010961A (es) 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ES2274035T3 (es) 2001-06-01 2007-05-16 Vertex Pharmaceuticals Incorporated Compuestos de tiazol utiles como inhibidores de proteina quinasas.
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
CA2447885C (en) 2001-06-22 2009-05-12 The Procter & Gamble Company Fabric care compositions for lipophilic fluid systems
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
NZ530524A (en) 2001-07-19 2006-12-22 Pharmacia Italia S Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
US6872533B2 (en) 2001-07-27 2005-03-29 The Regents Of The University Of California STK15 (STK6) gene polymorphism and methods of determining cancer risk
WO2003011287A1 (en) 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazolon derivatives as inhibitors of gsk-3
AU2002342607B2 (en) 2001-08-06 2006-10-19 Pharmacia Italia S.P.A. Aminoisoxazole derivatives active as kinase inhibitors
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1427707A1 (en) 2001-09-19 2004-06-16 Pharmacia Corporation Substituted indazole compounds for the treatment of inflammation
US6849653B2 (en) 2001-09-19 2005-02-01 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
MXPA04002667A (es) 2001-09-19 2004-06-18 Pharmacia Corp Compuestos de pirazolilo sustituido para el tratamiento de la inflacion.
EP1427706B1 (en) 2001-09-19 2007-05-30 Pharmacia Corporation Substituted pyrazolo compounds for the treatment of inflammation
NZ531765A (en) 2001-09-26 2006-02-24 Pharmacia Italia S Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
ES2333702T3 (es) 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7179826B2 (en) 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7091343B2 (en) 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003220300A1 (en) 2002-03-15 2003-09-29 Binch, Hayley Compositions useful as inhibitors of protein kinases
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
SE0200979D0 (sv) 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
WO2003086403A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003087395A2 (en) 2002-04-15 2003-10-23 Inserm Methods to identify anti-tumoral agents inhibiting rasgap / aurora kinase interactions
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003092607A2 (en) 2002-05-01 2003-11-13 Vertex Pharmaceuticals Incorporated Crystal structure of aurora-2 protein and binding pockets thereof
AU2003227741A1 (en) 2002-05-17 2003-12-02 Pharmacia Italia S.P.A. Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
MXPA04011930A (es) 2002-05-31 2005-03-31 Yamanouchi Pharma Co Ltd Derivados de tetrahidropirano.
FR2840905B1 (fr) 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
WO2003107002A1 (ja) 2002-06-12 2003-12-24 株式会社アクシアバイオサイエンス ｃｈｆｒタンパク質により触媒されるオーロラキナーゼＡ及びオーロラキナーゼＢのポリユビキチン化反応
CA2486215A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
JP4570955B2 (ja) 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
US20040197792A1 (en) 2002-07-15 2004-10-07 Sugen, Inc. Novel Kinases
CA2492673A1 (en) 2002-07-17 2004-01-22 Pharmacia Italia S.P.A. Heterobicyclic pyrazole derivatives as kinase inhibitors
CA2493637A1 (en) 2002-07-25 2004-02-12 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1526852A1 (en) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DE60319836T2 (de) 2002-07-25 2009-05-07 Pfizer Italia S.R.L. Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
US7304071B2 (en) 2002-08-14 2007-12-04 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
TW200413378A (en) * 2002-09-23 2004-08-01 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
US6909001B2 (en) 2002-12-12 2005-06-21 Pharmacia Corporation Method of making tricyclic aminocyanopyridine compounds
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
WO2004056812A1 (en) 2002-12-23 2004-07-08 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
EP1575946A1 (en) 2002-12-24 2005-09-21 AstraZeneca AB Quinazoline compounds
MY136174A (en) 2002-12-24 2008-08-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
WO2004058782A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Therapeutic quinazoline derivatives
CL2004000016A1 (es) 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
US20040242613A1 (en) 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
US20050266409A1 (en) 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
EP1592389B1 (en) 2003-02-14 2009-04-22 Laboratoires Serono SA Piperazine-2-carboxamide derivatives
WO2004071507A1 (en) 2003-02-17 2004-08-26 Pharmacia Italia S.P.A. Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DK1599478T3 (da) 2003-02-26 2007-09-17 Boehringer Ingelheim Pharma Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
BRPI0408486A (pt) 2003-03-11 2006-04-04 Pharmacia Italia Spa derivados de biciclopirazol ativos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo-os
CA2522176A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
US7223766B2 (en) * 2003-03-28 2007-05-29 Scios, Inc. Bi-cyclic pyrimidine inhibitors of TGFβ
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2004090106A2 (en) 2003-04-04 2004-10-21 Vertex Pharmaceuticals Incorporated Crystal structures of human pim-1 kinase protein complexes and binding pockets thereof, and uses thereof in drug design
JP4709139B2 (ja) 2003-04-16 2011-06-22 アストラゼネカ アクチボラグ 癌の治療のためのキナゾリン誘導体
CA2522435C (en) 2003-04-24 2011-04-12 Merck & Co., Inc. Inhibitors of akt activity
CA2522262A1 (en) 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
EP1620095A4 (en) 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY
EP1622616B1 (en) 2003-04-24 2011-06-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US20040242559A1 (en) 2003-04-25 2004-12-02 Aventis Pharma S.A. Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
AU2004255153B2 (en) 2003-05-01 2007-11-22 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
DE602004029242D1 (en) 2003-05-01 2010-11-04 Bristol Myers Squibb Co Pyrazolamidverbindungen
WO2005000200A2 (en) 2003-05-09 2005-01-06 Sugen, Inc. Novel kinases
AU2004240772B2 (en) 2003-05-22 2011-04-28 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
EP1635837B1 (en) 2003-06-02 2008-07-16 AstraZeneca AB (3-((quinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
AU2004249730A1 (en) 2003-06-20 2004-12-29 Novartis Vaccines And Diagnostics, Inc. Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents
US20050065171A1 (en) 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
GB0315657D0 (en) 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
CA2531142A1 (en) 2003-07-03 2005-01-13 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
EP1641775B1 (en) 2003-07-03 2009-02-18 Euro-Celtique S.A. 2-pyridine alkyne derivatives useful for treating pain
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0315966D0 (en) 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP1648900A4 (en) 2003-07-11 2010-02-10 Ariad Pharma Inc PHOSPHORUS MACROCYCLES
EA011300B1 (ru) 2003-07-16 2009-02-27 Янссен Фармацевтика Н.В. Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3
ATE370142T1 (de) 2003-07-16 2007-09-15 Janssen Pharmaceutica Nv Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
AU2004261400A1 (en) 2003-07-21 2005-02-10 Laboratoires Serono Sa Alkynyl aryl carboxamides
DK1648878T3 (da) 2003-07-24 2009-08-10 Euro Celtique Sa Piperidinforbindelser og farmaceutiske sammensætninger, som indeholder dem
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US20050026984A1 (en) 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products
AU2004261484A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
WO2005012298A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
US7094791B2 (en) 2003-07-31 2006-08-22 Avalon Pharmaceuticals, Inc. Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
JP2007512230A (ja) 2003-08-20 2007-05-17 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼ阻害剤として有用な（４−アミノ−１，２，５−オキサジアゾール−４−イル）−ヘテロ芳香族化合物
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
EP1667995A1 (en) 2003-09-12 2006-06-14 Applied Research Systems ARS Holding N.V. Benzimidazole acetonitriles
EP1664030A1 (en) 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
CA2539049A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
MXPA06003110A (es) 2003-09-17 2006-06-20 Icos Corp Uso de inhibidores de chk1 para controlar la proliferacion celular.
CA2539064A1 (en) 2003-09-17 2005-04-21 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
EP1664046B1 (en) 2003-09-19 2009-06-17 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
ES2284054T3 (es) 2003-10-14 2007-11-01 Pharmacia Corporation Compuestos de pirazinona sustituidos para el tratamiento de la inflamacion.
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2542076C (en) 2003-10-14 2013-02-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
KR20060123164A (ko) 2003-10-17 2006-12-01 아스트라제네카 아베 암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
WO2005037797A1 (en) 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
JP5164380B2 (ja) 2003-10-21 2013-03-21 サイクラセル リミテッド ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用
CA2542514A1 (en) 2003-10-23 2005-05-06 Pharmacia Corporation Pyrimidine compounds for the treatment of inflammation
WO2005044270A1 (en) 2003-11-04 2005-05-19 4Sc Ag Oxadiazolopyrazine derivatives as pharmaceutically active compounds
WO2005047266A1 (en) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP1791831A4 (en) 2003-11-19 2009-07-08 Signal Pharm Llc METHOD FOR THE TREATMENT OF DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES
FR2864084B1 (fr) 2003-12-17 2006-02-10 Aventis Pharma Sa Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments
EP1773807A2 (en) 2004-06-14 2007-04-18 Takeda San Diego, Inc. Kinase inhibitors
FR2876377B1 (fr) 2004-10-11 2007-03-16 Univ Claude Bernard Lyon Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2610347A1 (en) 2005-06-09 2006-06-08 Boehringer Ingelheim International Gmbh Alpha-carbolines as cdk-1 inhibitors
US7442700B2 (en) * 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors

Also Published As

Publication number Publication date
EP1812439B2 (en) 2017-12-06
WO2006044687A3 (en) 2006-07-20
JP2013121966A (ja) 2013-06-20
WO2006044687A2 (en) 2006-04-27
EP1812439B1 (en) 2010-09-01
EP1812439A2 (en) 2007-08-01
JP2012102121A (ja) 2012-05-31
US20100216765A1 (en) 2010-08-26
JP2008516973A (ja) 2008-05-22
US20060084650A1 (en) 2006-04-20
US8288536B2 (en) 2012-10-16
DE602005023333D1 (de) 2010-10-14
JP5524171B2 (ja) 2014-06-18
US7713973B2 (en) 2010-05-11

Similar Documents

Publication Publication Date Title
ATE479687T1 (de) Kinaseinhibitoren
MY146989A (en) Kinase inhibitors
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
WO2007117995A3 (en) Kinase inhibitors
WO2007028135A3 (en) Imidazopyridine compounds
WO2008055236A3 (en) Mapk/erk kinase inhibitors
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
WO2007061923A3 (en) Glucokinase activators
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
JO2985B1 (ar) مثبطات كينازmapk/erk
WO2007075847A3 (en) Glucokinase activators
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
TNSN08191A1 (en) Kinase inhibitors
TN2009000151A1 (en) Mapk/erk kinase inhibitors
WO2008115890A3 (en) Mapk/erk kinase inhibitors
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
NO20091817L (no) Kinase inhibitorer
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2008045834A3 (en) Kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties